InspireMD Inc

Insider buying by Stuka Paul boosts confidence in InspireMD’s biotech stock despite recent decline, hinting at a potential rebound as its acute myocardial infarction device advances.

Insider buying at InspireMD continues as senior executive Stuka Paul adds 10,000 shares at $1.16, signaling confidence despite a 53 % YTD decline.

Insider buying spurs confidence in InspireMD’s cardiology platform; Paul Stuka’s recent bulk purchases suggest long‑term upside amid market volatility.

Insider buying surges as Ward Scott R. and colleagues pile in on InspireMD stock, signaling renewed confidence amid a declining price and weak fundamentals. Click for insights on what this could mean for investors and the company’s future.